In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Dario Campana, MD, PhD
Member, St. Jude Faculty
Vice Chair for Laboratory Research, Oncology
Professor of Pediatrics, UT College of Medicine
Departments
Oncology
Pathology
Contact Information
Dario Campana, MD, PhD
Oncology
Pathology
MS 344, Room D4047
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: dario.campana@stjude.org
Phone: (901) 595-2528
FAX: (901) 595-3749
Education
MD - University of Torino, Italy
PhD - University of Milano, Italy
Research Interests
- Novel approaches to the classification, monitoring and treatment of leukemia and lymphoma
- Hematopoietic microenvironment
Selected Publications
Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, Campana D. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the Children’s Oncology Group. J Clin Oncol 2009 (in press).
Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D.Replicative potential of human natural killer cells. Br J Haematol 145: 606-613, 2009.
Fujisaki H, Kakuda H, Shimasaki N, Lockey T, Eldridge PW, Leung W, Campana D.Expanded natural killer cells for cell therapy of acute myeloid leukemia. Cancer Res 69:4010-4017, 2009.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui C6, Smith M, Hunger SP, Willman CL, Downing JR, and the Children's Oncology Group. Deletion of IKZF1 (IKAROS) is associated with poor prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009.
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Rubnitz JE, Pui CH, Downing JR, Campana D. A new biologic subtype of very high risk acute lymphoblastic leukemia. Lancet Oncology 10:147-156, 2009.
Yang J, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds S, Trevino L, French D, Campana D, Downing JR, Evans W, Pui CH, Devidas M, Bowman PW, Camitta B, Willman C, Davies S, Borowitz M, Carroll W, Hunger S, Relling M. Genome-wide interrogation of germline genetic variations associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403, 2009.
Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH, Downing JR, Campana D. A set of genes that regulate cell proliferation predict treatment outcome in childhood acute lymphoblastic leukemia. Blood 110:1271-1277, 2007.
Iwamoto S, Mihara K, Downing JR, Pui C-H, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117:1049-1057, 2007.
Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, Pui CH, Downing JR, Campana D. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 108:1050-1057, 2006.
Coustan-Smith E, Ribeiro RC, Stow P, Zhou Y, Pui CH, Rivera GK, Pedrosa F, Campana D. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 108: 97-102, 2006.
Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383, 2005.
Neale GAM, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui C-H, Campana D. Comparative analysis of polymerase chain reaction and flow cytometry for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 18: 934-938, 2004.
Imai C, Mihara K, Andreansky M, Nicholson IC, Pui C-H, Geiger TG, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676-684, 2004.
Coustan-Smith E, Gajjar A, Hijiya N, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Andreansky M, Hancock ML, Pui CH, Campana D. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 18: 499-504, 2004.
Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S, Andreansky M, Behm FG, Raimondi SC, Shurtleff SA, Downing JR, Campana D. Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 123: 243-252, 2003.
Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui C-H, Campana D. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 100: 2399-2402, 2002.
Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D. Prognostic significance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 100: 52-58, 2002.
Yeoh E-J, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui C-H, Evans WE, Naeve C, Wong L, Downing JR. Classification, subtype discovery and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143, 2002.
Chen J-S, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui C-H, Campana D. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 97: 2115-2120, 2001.
Srivannaboon K, Shanafelt AB, Todisco E, Behm FG, Raimondi SC, Pui C-H, Campana D. An interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. Blood 97: 752-758, 2001.
Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui C-H, Campana D. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96: 2691-2696, 2000.
Coustan-Smith E, Behm FG, Sanchez J, Hancock ML, Boyett JM, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui C-H, Campana D. Immunologic detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet 351:550-554, 1998.
Last update: May 2009
